Proteins for life
ExpreS2ion develops a portfolio of vaccines for diseases such as COVID-19, influenza and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system, ExpreS2, that is recognized for handling even the toughest protein challenges.
The company also collaborates on additional projects, including several malaria vaccines, and offers a range of protein expression and production services from discovery to pre-clinical development and cGMP production.
Latest press release
ExpreS2ion to participate in upcoming events
Hørsholm, Denmark, 1 June 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the 2023 BIO International Convention (5-8 June), Aktiespararna’s Small-Cap Day (13 June), and the 2023 Virus-Like Particle & Nano-Particle Vaccines Conference (27-29 June).Read more